Multi-Serotype AAV Capsid Antibody for Universal Vector Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research on AAV viral delivery vectors lacks a universal and effective serological detection method for viral capsid proteins, as different AAV serotypes have varying targeting properties and expression efficiencies, necessitating a more specific and versatile detection tool.
Innovation Solution
Development of a monoclonal antibody against capsid proteins of multiple AAV serotypes, comprising specific heavy and light chain CDR sequences and variable regions, which can recognize VP1, VP2, and VP3 proteins across various AAV serotypes, facilitating the development of a detection kit.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple different monoclonal antibodies are developed for different AAV serotypes, then detection coverage of various serotypes is improved, but device complexity and development time increase
Solution Approach 1:
The patent develops a universal monoclonal antibody (5G4-1) that can detect multiple AAV serotypes (AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAVDJ, and AAVrh.1) simultaneously. This single antibody targets a conserved epitope region in the capsid proteins across different serotypes, eliminating the need for multiple serotype-specific antibodies and simplifying the detection system while maintaining broad coverage
2Measurement precision
If serotype-specific detection methods are used for each AAV variant, then measurement precision for specific serotypes is improved, but productivity and ease of operation decrease
Solution Approach 1:
The monoclonal antibody 5G4-1 provides a universal detection solution that maintains measurement precision across multiple serotypes while significantly improving productivity. By targeting a conserved region in the capsid proteins that is present across AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAVDJ, and AAVrh.1, the antibody enables simultaneous detection of all these serotypes in a single assay, eliminating the need for multiple separate detection procedures
3Ease of operation
If a universal monoclonal antibody is developed for multiple AAV serotypes, then ease of operation and productivity are improved, but measurement precision for distinguishing specific serotypes may worsen
Solution Approach 1:
The patent acknowledges that the universal antibody 5G4-1 is optimized for detecting the presence and purity of AAV vectors across multiple serotypes rather than distinguishing between them. The antibody targets a conserved epitope in the capsid proteins that is present across AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAVDJ, and AAVrh.1, providing excellent ease of operation and productivity for quality control applications while recognizing that serotype-specific differentiation would require additional serotype-specific reagents
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The monoclonal antibody enables specific detection and functional verification of AAV viral delivery vectors, enhancing the development of a universal detection kit capable of recognizing multiple AAV serotypes.
Implementation Method 1
a monoclonal antibody against capsid proteins of multiple AAV serotypes... which can recognize VP1, VP2, and VP3 proteins across various AAV serotypes
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention belongs to the field of virus detection and diagnosis, and relates to a monoclonal antibody against capsid proteins of multiple AAV serotypes, a preparation method therefor, and the use thereof. Provided in the present invention are a rabbit monoclonal antibody against capsid proteins of multiple AAV serotypes, and amino acid sequences of a heavy-chain variable region and a light-chain variable region of same. Said rabbit monoclonal antibody provided by the present invention can specifically bind to capsid proteins VP1, VP2 and VP3 of multiple AAV serotypes, and thus can be used for detecting AAV antigens. The monoclonal antibody against capsid proteins of multiple AAV serotypes provided by the present invention enables and facilitates research and development processes of gene therapy vectors and detection of AAVs in basic scientific research.